SLS
Sellas Life Sciences Group I
NASDAQ · Biotechnology
$3.73
+0.20 (+5.67%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 353.66M | 369.01M | 305.89M |
| Net Income | 19.39M | 21.88M | 20.34M |
| EPS | — | — | — |
| Profit Margin | 5.5% | 5.9% | 6.7% |
| Rev Growth | -7.4% | -1.2% | +17.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 144.09M | 139.48M | 147.73M |
| Total Equity | 382.94M | 344.76M | 361.90M |
| D/E Ratio | 0.38 | 0.40 | 0.41 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 24.66M | 25.78M | 21.04M |
| Free Cash Flow | 20.13M | 23.20M | 18.29M |